Everolimus

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis

Conditions

Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma

Trial Timeline

Jan 1, 2007 → Jan 1, 2014

NCT ID

NCT00411619

About Everolimus

Everolimus is a phase 1/2 stage product being developed by Novartis for Tuberous Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00411619. Target conditions include Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma.

What happened to similar drugs?

1 of 8 similar drugs in Tuberous Sclerosis were approved

Approved (1) Terminated (1) Active (6)

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3

🔄Everolimus + PlaceboNovartisPhase 3

🔄RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3

🔄everolimusNovartisPhase 3

❌GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-PJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00655252	Pre-clinical	Completed	—	—	Metastatic Renal Cell Cancer
NCT05108740	Pre-clinical	Completed	—	—	Advanced Hormone Receptor Positive (HR+) Breast Cancer
NCT05252585	Approved	Active	May 1, 2023	Nov 25, 2026	Renal Angiomyolipoma
NCT03525834	Approved	Completed	Nov 9, 2018	Sep 25, 2020	Renal Angiomyolipoma
NCT02962414	Phase 3	Active	Jun 8, 2017	Aug 13, 2027	Tuberous Sclerosis Complex
NCT02842749	Approved	Completed	Mar 14, 2016	Feb 22, 2024	Pancreatic Neuroendocrine Tumors
NCT02429869	Approved	Completed	Feb 24, 2016	Jan 31, 2018	HIV
NCT02539459	Phase 2	Terminated	Sep 23, 2015	Aug 20, 2018	Sporadic Angiomyolipomas (AMLs)
NCT02687958	Phase 2	UNKNOWN	May 1, 2015	Dec 1, 2023	Neuroendocrine Carcinoma
NCT02376985	Phase 3	Completed	Mar 26, 2015	Oct 16, 2018	Breast Cancer
NCT02338609	Approved	Completed	Dec 17, 2014	Dec 18, 2023	Growth and Development
NCT02236572	Phase 2	Terminated	Nov 29, 2014	Mar 1, 2021	Breast Cancer
NCT02273752	Phase 2	Terminated	Nov 1, 2014	Dec 1, 2015	Estrogen Receptor-positive Breast Cancer
NCT02201212	Phase 2	Completed	Sep 1, 2014	Jun 1, 2019	TSC1
NCT01864070	Phase 1	Withdrawn	May 1, 2014	—	Liver Cancer
NCT01997255	Phase 2	Withdrawn	Apr 1, 2014	Apr 1, 2016	Sturge Weber Syndrome
NCT02096107	Approved	Completed	Feb 1, 2014	May 1, 2017	Graft Dysfunction
NCT02017860	Phase 2	Completed	Jan 16, 2014	Apr 25, 2019	Neoplasms
NCT01636466	Phase 3	Terminated	Jun 1, 2013	May 1, 2014	Kidney Failure, Chronic
NCT01609673	Pre-clinical	Terminated	Mar 1, 2013	May 1, 2013	End Stage Renal Failure With Renal Transplant

Competing Products

13 competing products in Tuberous Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Everolimus + Placebo	Novartis	Phase 3	40
RAD001	Novartis	Phase 1/2	32
Placebo + Everolimus (RAD001)	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
everolimus (RAD001)	Novartis	Phase 1/2	32
everolimus	Novartis	Phase 3	44
sirolimus	Pfizer	Phase 2	31
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
GWP42003-P	Jazz Pharmaceuticals	Phase 3	37
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	37
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	44